. 2023 Jul 13;13:1142168. doi: 10.3389/fonc.2023.1142168

Table 1.

Baseline Characteristics of 162 Patients with HCC.

Variables	No.(%)	SIRI		χ²	P value	PLR		χ²	P value	NLR		χ²	P value	SII		χ²	P value
		≼	>			≼	>			≼2.231	>2.231			≼353.64	>353.64
		0.785	0.785			86.421	86.421			≼2.231	>2.231			≼353.64	>353.64
All patients	162(100.0)	93	69			74	88			98	64			93	69
Gender
Male	125(77.2)	71	54	0.083	0.774	61	64	2.148	0.143	78	47	0.832	0.362	73	52	0.221	0.639
Female	37(22.8)	22	15	0.083	0.774	13	24	2.148	0.143	20	17	0.832	0.362	20	17	0.221	0.639
Age
≤60	107(66.0)	64	43	0.746	0.388	55	52	4.160	0.041	65	42	0.008	0.927	63	44	0.279	0.597
>60	55(34.0)	29	26	0.746	0.388	19	36	4.160	0.041	33	22	0.008	0.927	30	25	0.279	0.597
BMI
≼28.0	150(92.5)	80	63	1.068	0.301	67	76	0.677	0.410	86	57	0.064	0.800	84	59	0.887	0.346
>28.0	12(7.5)	13	6	1.068	0.301	7	12	0.677	0.410	12	7	0.064	0.800	9	10	0.887	0.346
Diabetes
No	151(93.2)	86	65	0.187	0.665	70	81	0.413	0.521	91	60	0.049	0.825	87	64	0.040	0.842
Yes	11(6.8)	7	4	0.187	0.665	4	7	0.413	0.521	7	4	0.049	0.825	6	5	0.040	0.842
Alcohol
No	130(80.2)	74	56	0.063	0.802	60	70	0.060	0.807	79	51	0.021	0.885	76	54	0.299	0.584
Yes	32(19.8)	19	13	0.063	0.802	14	18	0.060	0.807	19	13	0.021	0.885	17	15	0.299	0.584
Family cancer history
No	150(92.5)	86	66	0.691	0.406	59	83	0.080	0.777	92	60	0.001	0.974	89	63	1.321	0.250
Yes	12(7.5)	7	3	0.691	0.406	5	5	0.080	0.777	6	4	0.001	0.974	4	6	1.321	0.250
HBsAg (+)
No	27(16.7)	15	12	0.045	0.831	8	19	3.363	0.067	15	12	0.331	0.565	9	18	7.680	0.006
Yes	135(83.3)	78	57	0.045	0.831	66	69	3.363	0.067	83	52	0.331	0.565	83	51	7.680	0.006
Tumor number
Multiple	24(14.8)	15	9	0.299	0.585	11	13	0.000	0.987	16	8	0.449	0.503	16	8	0.988	0.320
Solitary	138(85.2)	78	60	0.299	0.585	63	75	0.000	0.987	82	56	0.449	0.503	77	61	0.988	0.320
Tumor diameter
≼5	101(62.3)	69	32	13.056	0.000	55	46	8.326	0.004	69	32	6.869	0.009	70	31	15.533	0.000
>5	61(37.7)	24	37	13.056	0.000	19	42	8.326	0.004	29	32	6.869	0.009	23	38	15.533	0.000
Differentiation
poor	60(37.0)	30	30	2.138	0.144	23	37	2.072	0.150	27	33	9.572	0.002	30	30	2.138	0.144
Moderate and well	102(63.0)	63	39	2.138	0.144	51	51	2.072	0.150	71	31	9.572	0.002	63	39	2.138	0.144
Vascular invasion
No	147(90.7)	87	60	2.049	0.152	70	77	2.408	0.121	91	56	1.322	0.250	86	61	0.780	0.377
Yes	15(9.3)	6	9	2.049	0.152	4	11	2.408	0.121	7	8	1.322	0.250	7	8	0.780	0.377
Liver cirrhosis
No	26(16.0)	14	12	0.161	0.689	6	20	6.376	0.012	16	10	0.014	0.905	13	13	0.695	0.404
Yes	136(84.0)	79	57	0.161	0.689	68	68	6.376	0.012	82	54	0.014	0.905	80	56	0.695	0.404
N
No	157(97.0)	90	67	0.014	0.905	73	84	1.371	0.242	95	62	0.001	0.982	91	66	0.639	0.424
Yes	5(3.0)	3	2	0.014	0.905	1	4	1.371	0.242	3	2	0.001	0.982	2	3	0.639	0.424
AJCC stage
I-II	154(95.0)	88	66	0.089	0.765	72	82	1.450	0.228	92	62	0.741	0.389	88	66	0.089	0.765
III-IV	8(5.0)	5	3	0.089	0.765	2	6	1.450	0.228	6	2	0.741	0.389	5	3	0.089	0.765
Postoperative treatment (Ablation or TACE)
No	135(83.3)	78	57	0.045	0.831	64	71	0.975	0.323	88	47	7.459	0.006	81	54	2.227	0.136
Yes	27(16.7)	15	12	0.045	0.831	10	17	0.975	0.323	10	17	7.459	0.006	12	15	2.227	0.136
AFP>400
No	112(69.1)	65	47	0.059	0.809	70	42	0.611	0.434	65	47	0.059	0.809	73	39	0.152	0.697
Yes	50(30.9)	28	22	0.059	0.809	28	22	0.611	0.434	28	22	0.059	0.809	31	19	0.152	0.697
Child-Pugh grading
A	154(95.0)	89	65	0.189	0.664	72	82	1.450	0.228	94	60	0.388	0.533	90	64	1.364	0.240
B	8(5.0)	4	4	0.189	0.664	2	6	1.450	0.228	4	4	0.388	0.533	3	5	1.364	0.240

SIRI, Systemic Inflammation Response Index; PLR, Platelet-to-lymphocyte ratio; NLR, Neutrophil-to-Lymphocyte Ratio; SII, Systemic Immune-Inflammation Index; BMI, Body mass index; N, Regional lymph node metastasis; AFP, alpha fetoprotein; TACE, transcatheter arterial chemoembolization.